However, clinical trials of drugs which target the mineralocorticoid receptor, renin-angiotensin system, natriuretic peptide degradation, vascular tone, and others have yielded mixed results in reducing fibrosis-related outcomes in patients with heart failure with preserved and reduced ejection fraction and ischaemic heart disease despite encouraging preclinical data (Reviewed in38). The gene discussed is NR3C2; the disease is heart disorder.